Granules India Ltd - Company Profile
Powered by 
All the data and insights you need on Granules India Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Granules India Ltd Strategy Report
- Understand Granules India Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Granules India Ltd (Granules) is a vertically integrated pharmaceutical company.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Granules India Ltd (Granules) strives to provide innovative products focused on areas related to active pharmaceutical ingredient, pharmaceutical formulation intermediaries and finished doses. The R&D pipeline is focused on PFT and formulation development including pre-formulation development, formulation development, analytical development and ANDA/dossier filings. In FY2023, the company invested INR997.2 million on its R&D activities, which as a percentage of revenue stood at 2.2%. The company has four R&D facilities located in Pune and Hyderabad, India. As of FY2023, the company held eight granted patents and 20 pending patent applications in active prosecution; and it has received five ANDA approvals worldwide.
Business Segments
- Active Pharmaceutical Ingredients (API)
- Finished Dosages (FD)
- Pharmaceutical Formulation Intermediates (PFI)
Overview
Focuses on the production and supply of Paracetamol, Ibuprofen, Metformin, Methocarbamol and Guaifenesin APIs.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
- Manufactures prescribed and over-the-counter products. - Provides multiple finished dosage forms comprising caplets; tablets such as rapid release tablets, extended-release (ER), bilayer tablets; press-fit capsules in bulk, blister packs, and bottles.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
- Offers pre-formulation development, formulation development, analytical development and ANDA/ dossier filings and PFI’s that are to be taken from drum to hopper. - Operates through its facilities present in Jeedimetla and Gagillapu to process into Finished Dosages. - It has a batch processing capability of six tonnes.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer